{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:04:09Z","timestamp":1789427049457,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Women with hereditary breast cancer factors are more likely to be infertile and tend to receive fertility treatments. The safety of fertility treatments that contain hormone-related medications for ovarian stimulation has gained wide attention; however, evidence of the safety of fertility treatments is limited. This study aims to assess the association between fertility treatments and the incidence rate of breast cancer in women with a family history of breast cancer or <jats:italic>BRCA<\/jats:italic> mutations. A literature search was conducted in PubMed, Cochrane Library, and Embase. Studies concerning the effect of fertility treatments on breast cancer risk in genetically susceptible women were included. The fixed and random effects models were used to estimate the summary effects. Risk Of Bias In Non-randomized Studies - of Interventions instrument was used to assess the risk of bias in the included studies. A total of 5,282 studies were screened. Five cohort studies and three case-control studies were included. Breast cancer risk was not significantly increased by fertility treatments in general genetically susceptible women [pooled odds ratio (OR) 1.18, 95% confidence interval (CI) 0.96\u20131.45], women with a family history of breast cancer (pooled OR 1.35, 95% CI 0.97\u20131.89), or women with BRCA mutations (pooled OR 1.02, 95% CI 0.74\u20131.4). In subgroup analyses, there was no significant increase in breast cancer risk whether in BRCA1 mutation carriers (pooled OR 1.18, 95% CI 0.81\u20131.72), BRCA2 mutation carriers (pooled OR 0.54, 95% CI 0.09\u20133.34), or in the women treated with <jats:italic>in vitro<\/jats:italic> fertilization (pooled OR 0.75, 95% CI 0.51\u20131.1), clomiphene citrate (pooled OR 1.07, 95% CI 0.78\u20131.45) or gonadotropins (pooled OR 1.32, 95% CI 0.8\u20132.18). This is the first meta-analysis concerning the impact of fertility treatments on breast cancer risk in genetically susceptible women. Despite the finding that fertility treatment did not significantly increase breast cancer risk in genetically susceptible women, large prospective cohorts with more detailed information are required. Further investigations are needed to explore subtypes of breast cancer, genetic background of hormone-related breast cancer, and the association between BRCA mutations and the incidence of hormone receptor-positive breast cancer. <\/jats:p><jats:sec><jats:title>Registration number<\/jats:title><jats:p>PROSPERO(CRD42021281336).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.986477","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T04:50:48Z","timestamp":1663044648000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaojing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruqiya","family":"Pervaiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanwang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13045-021-01213-z","article-title":"Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019","volume":"14","author":"Lin","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1530\/JME-18-0094","article-title":"Hormone therapy and breast cancer: Emerging steroid receptor mechanisms","volume":"61","author":"Perkins","year":"2018","journal-title":"J Mol Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"hoaa009","DOI":"10.1093\/hropen\/hoaa009","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI","volume":"2020","author":"Bosch","year":"2020","journal-title":"Hum Reprod Open"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2017.08.011","article-title":"Estrogen and progesterone signalling in the normal breast and its implications for cancer development","volume":"466","author":"Hilton","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.beem.2018.10.002","article-title":"Pharmacology of medications used for ovarian stimulation","volume":"33","author":"Quaas","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3390\/ijms18071587","article-title":"Human chorionic gonadotropin and breast cancer","volume":"18","author":"Schuler-Toprak","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10549-017-4325-2","article-title":"Family history and risk of breast cancer: an analysis accounting for family structure","volume":"165","author":"Brewer","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.09.006","article-title":"Ovarian reserve of women with and without BRCA pathogenic variants: A systematic review and meta-analysis","volume":"60","author":"Gasparri","year":"2021","journal-title":"Breast"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02880","article-title":"Association of germline BRCA pathogenic variants with diminished ovarian reserve: A meta-analysis of individual patient-level data","volume":"39","author":"Turan","year":"2021","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2017.12.004","article-title":"BRCA mutations and reproduction","volume":"109","author":"Daum","year":"2018","journal-title":"Fertil Steril"},{"key":"B13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.fertnstert.2021.01.044","article-title":"Risk of breast cancer in women treated with ovarian stimulation drugs for infertility: a systematic review and meta-analysis","volume":"116","author":"Beebeejaun","year":"2021","journal-title":"Fertil Steril"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaa293","article-title":"Fertility treatment and cancers-the eternal conundrum: a systematic review and meta-analysis","volume":"36","author":"Barcroft","year":"2021","journal-title":"Hum Reprod"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmt034","article-title":"IVF and breast cancer: a systematic review and meta-analysis","volume":"20","author":"Sergentanis","year":"2014","journal-title":"Hum Reprod Update"},{"key":"B16","doi-asserted-by":"publisher","first-page":"zrab149","DOI":"10.1093\/bjsopen\/zrab149","article-title":"Fertility treatment and breast-cancer incidence: meta-analysis","volume":"6","author":"Cullinane","year":"2022","journal-title":"BJS Open"},{"key":"B17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/IGC.0b013e318277608b","article-title":"Meta-analysis on the possible association between in vitro fertilization and cancer risk","volume":"23","author":"Li","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10549-010-1140-4","article-title":"Fertility drugs and the risk of breast cancer: a meta-analysis and review","volume":"124","author":"Zreik","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-020-05690-4","article-title":"Use of fertility treatments in BRCA1\/2 mutation carriers and risk for ovarian and breast cancer: a systematic review","volume":"302","author":"Huber","year":"2020","journal-title":"Arch Gynecol Obstet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2021.02.030","article-title":"Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers","volume":"116","author":"Perri","year":"2021","journal-title":"Fertil Steril"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deab219","article-title":"Assisted reproductive technology treatment and risk of breast cancer: a population-based cohort study","volume":"36","author":"Vassard","year":"2021","journal-title":"Hum Reprod"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2021.06.011","article-title":"BRCA, breast cancer and in vitro fertilization: How should we advise our patients","volume":"116","author":"Garc\u00eda-Planells","year":"2021","journal-title":"Fertility Sterility"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: A proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Syn Meth"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0139-1","article-title":"Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1\/2 mutation carriers","volume":"119","author":"Derks-Smeets","year":"2018","journal-title":"Br J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-008-9175-0","article-title":"Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study","volume":"19","author":"Kotsopoulos","year":"2008","journal-title":"Cancer Causes Control"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/HUMREP\/11.2.300","article-title":"Fertility treatment and risk of breast cancer","volume":"11","author":"Braga","year":"1996","journal-title":"Hum Reprod"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh422","article-title":"Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study","volume":"19","author":"Gauthier","year":"2004","journal-title":"Hum Reprod"},{"key":"B31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3906\/sag-1709-54","article-title":"Risk factor assessment for breast cancer in north Cyprus: a comprehensive case-control study of Turkish Cypriot women","volume":"48","author":"Pervaiz","year":"2018","journal-title":"Turk J Med Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-13-0996","article-title":"Long-term relationship of ovulation-stimulating drugs to breast cancer risk","volume":"23","author":"Brinton","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3328-0","article-title":"Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies","volume":"150","author":"Gennari","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1529428","article-title":"Identifying breast cancer susceptibility genes - a review of the genetic background in familial breast cancer","volume":"58","author":"Wendt","year":"2019","journal-title":"Acta Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa023","article-title":"The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort","volume":"112","author":"Hu","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-013-1299-y","article-title":"The complex genetic landscape of familial breast cancer","volume":"132","author":"Melchor","year":"2013","journal-title":"Hum Genet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2020.04.07","article-title":"Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients","volume":"54","author":"Kim","year":"2020","journal-title":"J Pathol Transl Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/Familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Daly","year":"2021","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.986477\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T04:50:53Z","timestamp":1663044653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.986477\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":38,"alternative-id":["10.3389\/fendo.2022.986477"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.986477","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"article-number":"986477"}}